sEphB4-HSA + Pembrolizumab for Cancer
Trial Summary
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you are on systemic steroid therapy or any form of immunosuppressive therapy within 7 days before the trial starts. It's best to discuss your specific medications with the trial team.
Pembrolizumab has been approved for treating several types of cancer, including esophageal, gastroesophageal, and endometrial cancers, and has shown high response rates in melanoma patients. It works by helping the immune system attack cancer cells more effectively.
12345Pembrolizumab, also known as Keytruda, has been shown to be generally safe in humans, with common side effects including fatigue, rash, itching, and diarrhea. However, it can also cause less common immune-related side effects like inflammation of the lungs (pneumonitis), thyroid issues, and liver inflammation (hepatitis). In nonhuman primate studies, no significant toxic effects were observed.
45678The combination of sEphB4-HSA and pembrolizumab is unique because it combines a recombinant protein that targets the EphB4 receptor, potentially affecting tumor blood supply, with pembrolizumab, an immune checkpoint inhibitor that helps the immune system attack cancer cells. This dual approach may offer a novel mechanism of action compared to standard treatments.
123910Eligibility Criteria
This trial is for adults with certain advanced solid tumors, specifically metastatic or recurrent urothelial carcinoma that's resistant to platinum-based treatment, and locally advanced prostate cancer. Participants must have adequate organ function, no recent other treatments or surgeries, and agree to use contraception. Those with active pneumonitis, uncontrolled hypertension, known psychiatric disorders affecting cooperation, prior anti-PD-1/PD-L1 therapy or sEphB4-HSA are excluded.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
- Melanoma
- Non-small cell lung cancer (NSCLC)
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Renal cell carcinoma
- Cervical cancer
- Endometrial carcinoma
- Head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
- Melanoma
- Non-small cell lung cancer (NSCLC)
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Renal cell carcinoma
- Cervical cancer
- Endometrial carcinoma
- Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1